Home
Chemicals

Sector: Chemicals

Report urges companies to hunt for more value from their patents

PatSnap’s “State of IP” report reveals intelligence about patent value, monetisation strategies, IP department budgets and more

Nanoco eyeing further assertions following big-money Samsung pay-out, says CEO

Brian Tenner sits down with IAM to discuss the company’s win and future strategy

The fast-evolving cannabis patent dispute landscape

GW’s recent ANDA lawsuit is a landmark moment, but will remain untypical of cannabis IP litigation

Latest content

Legal challenges to the PTAB’s NHK-Fintiv discretionary denial regime mount

Life sciences companies are among those leading the way in going to court to get the current rules struck down

20 August 2021

Brazil on the cusp of passing landmark compulsory technology transfer law

Life sciences innovators may be compelled to hand over trade secrets, data and biological materials under legislation that now only requires President Bolsonaro’s signature to become law

19 August 2021

A defensive strategy for China can help multinationals avoid bad faith patent litigation

Companies can take steps to reduce the chance that they’re targeted with a low-quality patent

19 August 2021

New study shows surge in data-driven and computer-assisted healthcare patents

Boom in digital healthcare and bioinformatics IP requires strategic adjustments in both the life sciences and high-tech arenas

17 August 2021

$235 million CAFC decision creates confusion around skinny-label generics, says dissenting judge

The Federal Circuit hands down its second ruling in the carvedilol dispute between Teva and GSK, following widespread concern over its first

13 August 2021

Chinese court enforces trade secret arbitration award of over $100 million against Chinese company

Dow and Johnson Matthey welcome enforcement action, which comes on the heels of a civil trade secrets litigation win in a different Chinese court last year

12 August 2021

Pharma should make good use of the UPC from the beginning, says Bayer’s head of IP

There are a lot of potential benefits to the new system, but we need to integrate it into our strategies to make sure it works, explains Joerg Thomaier

11 August 2021